Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2025

Martínez-Castedo B, Camblor D G, Martín-Arana J, Carbonell-Asins J A, García-Micó B, Gambardella V, Huerta M, Roselló S, Roda D, Gimeno-Valiente F, Cervantes A, Tarazona N

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) analysis has emerged as a minimally invasive tool for detecting minimal residual disease (MRD) in colorectal cancer (CRC) patients. This enables dynamic risk stratification, earlier recurrence detection and optimized post-surgical treatment. Two primary methodologies have been developed for ctDNA-based MRD detection: tumor-informed strategies, which identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Neoplasm, Residual

Source

Identifiers

PMID: 39675560
DOI: 10.1016/j.annonc.2024.12.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy.PMID 39675560Read ↗

Minimal residual disease detection with circulating tumor DNA in colorectal cancer: current horizons and future perspectives in clinical applicationsSemantic proximity Read ↗

Colorectal Cancer Recurrence Prediction Using a Tissue-Free Epigenomic Minimal Residual Disease AssaySemantic proximity Read ↗

Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study.Semantic proximity Read ↗

Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC)Semantic proximity Read ↗

Risk stratification by minimal residual disease detection and ctDNA dynamics from personalised assays in stage II-III colorectal cancer in a UK multi-centre prospective study (TRACC Part B)Semantic proximity Read ↗

Beyond Binary MRD: Quantitative ctDNA Interpretation After Curative-Intent Surgery for Colorectal CancerSemantic proximity Read ↗

Use of Circulating Cell-Free DNA to Guide Precision Medicine in Patients with Colorectal Cancer.Semantic proximity Read ↗

Ultrasensitive tumour‐agnostic non‐invasive detection of colorectal cancer recurrence using ctDNA methylationSemantic proximity Read ↗

Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancerSemantic proximity Read ↗

Japanese Society of Medical Oncology clinical guidelines: Molecular testing for colorectal cancer treatment, 5th edition.Semantic proximity Read ↗

Bridging horizons beyond CIRCULATE-Japan: a new paradigm in molecular residual disease detection via whole genome sequencing-based circulating tumor DNA assaySemantic proximity Read ↗

Circulating tumor DNA in colorectal cancer: biology, methods and applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.